CClinicalTrials.gg
Not yet recruitingNCT07146334OASISUpdated Aug 28, 2025

Low Powered Colorectal Anastomosis After Rectal Excision (OASIS)

An observational study in Rectal Cancer and Surgery Indication, sponsored by Bordeaux Colorectal Institute. Not yet recruiting at 15 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Bordeaux Colorectal Institute · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

The objectiive of this prospective, international cohort is to compare two anastomotic techniques (DS vs TTSS) by collecting data during the surgery, and postoperatively (morbidity and functional outcomes).

The choice of technique is left to the discretion of the surgeon based on her/his practices.

Read the detailed description

There are a variety of available anastomotic techniques to facilitate restorative surgery following total mesorectal excision (TME) for rectal cancer. However, there is no good quality evidence demonstrating the superiority of any single technique with regards to the potential sequalae of restorative surgery including anastomotic leakage and functional impact. Double-stapled anastomotic technique (DST) for colorectal anastomosis is the most widely used technique worldwide. An alternative to DST is the hand-sewn coloanal anastomotic (CAA) technique, which is traditionally reserved for patients with ultralow rectal tumours requesting restorative surgery or in cases of technical difficulties whereby a low colorectal anastomosis is converted to a coloanal anastomosis. More recently, the Transanal Transection and Single Staple anastomosis (TTSS) technique has been described. The TTSS technique has the potential to mitigate the difficulties encountered with DST and the potential complications and long-term functional sequalae encountered with handsewn anastomosis. Moreover, powered mechanical circumferential staplers represent a significant advancement in colorectal surgery, particularly in performing anastomosis following rectal excision. These devices are designed to provide consistent staple formation and controlled tissue compression, reducing the variability associated with manual stapling.

AL has a significant impact on clinical, patient-reported, and oncological outcomes. To mitigate the impact of AL a diverting stoma is routinely used to protect the distal anastomosis and facilitate anastomotic healing, with these stomas reversed once the integrity and patency of the distal anastomosis is confirmed. However, there is a significant complication profile associated with the routine use of diverting stomas. Through the incorporation of appropriate pre-operative risk stratification and careful post-operative surveillance a selective stoma strategy is associated with good clinical and functional outcomes.

The use of Double-stapled anastomotic technique (DST) or Transanal Transection Single-Stappled (TTSS) by laparoscopic or robotic approach, using or not a defunctionning stoma could not be separately tested in randomized trial.

In this exploratory, observational, prospective, IDEAL stage 2b International cohort study, we aim to include 400 patients with resection rectal and low powered colorectal anastomosis.

02

Conditions studied

  • Rectal Cancer
  • Surgery Indication

Keywords

  • rectal cancer
  • Transanal Transection and Single Staple anastomosis (TTSS)
  • Double-stapled anastomotic (DS)
  • mechanical anastomosis
  • rectal surgery
  • anastomotic leakage
03

In context

Rectal Neoplasms

1,761 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

This study's planned enrollment of 400 is above the median of 160 across 413 observational studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

This is the only study on the registry with Bordeaux Colorectal Institute as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In this exploratory, observational, prospective, IDEAL stage 2b International cohort study, we aim to include 400 patients with resection rectal and low powered colorectal anastomosis. This study is to compare two anastomotic techniques (DS vs TTSS) by collecting data during the surgery, and postoperatively (morbidity and functional outcomes).

Surgeons at each center perform one or both techniques. When both types of stapling are possible, the choice of technique is made by the surgeon during the preoperative consultation, in the best interest of the patients, after a case-by-case assessment.

Inclusion criteria

  • Age ≥ 18
  • Patients with rectal cancer lower than 12 cm from the anal verge requiring either a stapling anastomosis below 7 cm from the anal verge,
  • Patients with powered mechanical anastomosis (INTOCARE devices)
  • Patients with no metastasis
  • Patients operated on by mini-invasive rectal excision (laparoscopic, robotic or TaTME);
  • Patients with or without defunctioning ileostomy;
  • Patients with or without neoadjuvant treatment;
  • Patient who benefits by medicare system;
  • Signed and dated informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients with handsewn anastomosis
  • Patients with perforated rectal cancer or preoperative pelvic sepsis ;
  • Patients with inflammatory bowel disease;
  • Patients operated on in emergency ;
  • Patients with extended-TME or pelvic exenteration;
  • Pregnancy or breast feeding period
  • Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to agree to participate in the study
  • Persons deprived of liberty or under guardianship
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Rectal surgery with powered mechanical anastomosis performed with DS or TTSS techniques

    This is an international cohort (France and other international centers) which consists of including patients undergoing rectal surgery with powered mechanical anastomosis performed with DS or TTSS techniques. Surgeons at each center perform one or both techniques. When both types of stapling are possible, the choice of technique is made by the surgeon during the preoperative consultation, in the best interest of the patients, after a case-by-case assessment.

06

What researchers measure

Primary outcomes

  1. To assess and compare the rate of anastomotic leakage at 1 month after rectal excision between double and single-stapling low colorectal anastomosis using advanced powered stapler

    Proportion of anastomotic leakage (clinical and radiological) at 1 month after rectal surgery between double- and single-stapling low colorectal anastomosis using advanced powered stapler.

    Time frame: From the surgery to one month

Secondary outcomes

  1. Overall morbidity and mortality rates at 1 month

    Postoperative morbidity and mortality according Clavien-Dindo classification at 1 month

    Time frame: At 1 month after the end of the surgery

  2. The rate of anastomotic leakage at 6 and 12 months after rectal surgery;

    Rate of defunctioning stoma at 1, 6 and 12 months after surgery;

    Time frame: At 12 month after the end of the surgery

  3. Quality of life with QLQ C30 questionnaire

    The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. This is a patients self-rating questionnaire that measures five functional scales (physical, role, social, emotional, and cognitive) three symptom scales (fatigue, pain, nausea and vomiting) A global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. Scores can be linearly transformed to provide a score from 0 to 100 REF. Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales. 9 dimensions will be assessed with: PF : Physical Functioning RF : Role Functioning CF : Cognitive Functioning EF : Emotional Functioning SF: Social Functioning FA : Fatigue PA : Pain NV : Nausea and Vomiting QL : Global health status

    Time frame: At 1, 6 and 12 months after rectal surgery

  4. Quality of life with QLQ CR29 questionnaire

    The QLQ-CR29 (Quality of life of rectal cancer patients with 29 questions) has five functional and 18 symptom scales. Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales.

    Time frame: At 1,6 and 12 months after rectal surgery

  5. Qualiy of life with EQ5D-5L

    Mean Score of the EQ-5D-5L Quality of Life The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).The questionnaire is a self-report survey that measures quality of life across 5 domains: : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state \- The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, numbered from 0 to 100. ( 100 means "the best health you can imagine" and 0 means "the worst health you

    Time frame: At 1, 6 and 12 months after rectal surgery

  6. Digestive function with LARS score

    The LARS questionnaire (low anterior resection score) evaluates bowel function. Five questions regarding incontinence for flatus and liquid stools, frequency, clustering and urgency for defecation are taken into account. The score ranges from 0 to 42 is divides into no LARS (0 to 20 points), minor LARS (21 to 29 points), and major LARS (30 to 42 points).

    Time frame: At 1, 6 and 12 months after rectal surgery

  7. Anal Incontinence with Wexner score ( or Vaizey score)

    The WEXNER score assesses the importance of anal incontinence, it varies from 0 to 20, where 20 corresponding to total anal incontinence The Vaizey score assesses the importance of anal incontinence score from 0-28 where 0 means better outcomes

    Time frame: At 1,6 and 12 months after rectal surgery

  8. Female Sexual Function Index (FSFI) scale scores

    Measured in female patients. The Female Sexual Function Index (FSFI) is a 19-item self-report inventory designed to assess female sexual function. It comprises six domains: desire, arousal ,lubrication orgasm, satisfaction, pain. The maximum score for each domain is 6.0, obtained by summing item responses and multiplying by a correction factor. The total composite sexual function score is a sum of domain scores and ranges from 2.0 (not sexually active and no desire) to 36.0.

    Time frame: At 1, 6 and 12 months after rectal surgery

  9. International Index of Erectile Function (IIEF)-5

    Measured in male patients IIEF assessment assesses to a limit the psychosexual background and the partner relationship, both considered important factors in the presentation of male sexual dysfunction. Scores of 0 to 5 are awarded to each of the 15 questions, then the scores are interpreted in the view of the5 domains from the original study. Domain A Erectile Function Domain B Orgasmic Function Domain C Sexual Desire Domain D Intercourse Satisfaction Domain E Overall Satisfaction

    Time frame: At 1,6 and 12 months after rectal surgery

  10. International Prostate Symptom Score (IPSS)

    The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).

    Time frame: At 1, 6 and 12 months after surgery

  11. Predictive factors for anastomotic fistula

    To identify predictive factors of anastomotic fistula from the surgery to 12 months Comparison of the clinical and perioperative data . The differences in proportions will be compared.

    Time frame: From the surgery to 12 months

07

Study locations

15 sites
  • Hôpital Universitaire de Belgique
    Leuven, Belgium
  • Hôpital Universitaire McGill
    Montreal, Canada
    • Larry LEE · Contact · larry.lee@mcgill.ca
    • Larry LEE · Principal investigator
    • Patrick CHARLEBOIS · Sub investigator
  • CHU de Quebec
    Québec, Canada
  • Hôpital Universitaire de Shanghai
    Shanghai, China
  • CHU de Besançon
    Besançon, 25030, France
  • Bordeaux Colorectal Institute
    Bordeaux, 33 000, France
  • Hôpital Bicêtre APHP
    Le Kremlin-Bicêtre, 94 270, France
  • CHU de Lyon
    Lyon, 69 495, France
  • Gp Hospitalier Diaconesses Croix St Simon
    Paris, 75 020, France
  • Hôpital Européen Georges Pompidou APHP
    Paris, 75012, France
    • Mehdi KAROUI · Contact · mehdi.karoui@aphp.fr · +33 (0)1 56 09 35 34
    • Mehdi KAROUI · Principal investigator
  • Hôpital Saint Antoine APHP
    Paris, 75012, France
    • Jérémie LEFEVRE · Contact · jeremie.lefevre@aphp.fr · +33 (0) 1 49 28 26 87
    • Jérémie LEFEVRE · Principal investigator
  • Hôpital Charles Nicolle
    Rouen, 76 031, France
  • Policlinique Universitaire Gemelli
    Roma, Italy
  • Hôpital General universitaire Madrid
    Madrid, Spain
  • Hôpital Universitaire de Vigo
    Vigo, Spain
    • Vincenzo VIGORITA · Contact · v.vigorita@gmail.com · +34
    • Vincezo VIGORITA · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There are no plans to share individual participant data(IPD) with other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146334
Lead sponsor
Bordeaux Colorectal Institute
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 28, 2025

Study contacts

Quentin QD DENOST, Prof
Contact
q.denost@bordeaux-colorectal-institute.fr
+ 33 (0)5 47 50 15 75
Hélène HMM MAILLOU-MARTINAUD, CRA
Contact
h.maillou.martinaud@bordeaux-colorectal-institute.fr
+33 6 68 68 68 05

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion